Jun 2026 (Q2 FY26) — Aug 13, 2026
Nektar Therapeutics Q2 FY26 — Phase III REZPEG Programs Advancing, Strong Cash Position
Read the full callNektar Therapeutics (NKTR) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Nektar Therapeutics earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 10.1 | −9.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -417.9 | −93.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -40.6 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$36.64 +2.40% · +$0.86
Performance −36.6% 1Y
1Y: $57.77 on 17 Oct 2025 → $36.64. High $100.35 (20 Apr 2026), low $35.12 (5 Feb 2026).
- Previous close
- $35.78
- 52-week range
- $35.12 – $100.35
- One year
- −41.83%
Overview
- Symbol
- NKTR
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Nektar Therapeutics earnings calls (NKTR)
Financials
What the filings say
Net profit, year on year: +2% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 24 | 29 | 10 | 11 | 12 | 22 | 11 | 10 |
| Expenses | 58 | 15 | 55 | 47 | 43 | 49 | 50 | 52 |
| Operating profit | -34 | 14 | -45 | -36 | -32 | -28 | -39 | -42 |
| Operating margin | −142.4% | 49.2% | −425.8% | −324.2% | −268.6% | −126.9% | −359.6% | −417.9% |
| Other income | -3 | -7 | -2 | -3 | -3 | -7 | -4 | 2 |
| Profit before tax | -37 | 7 | -46 | -39 | -35 | -35 | -43 | -40 |
| Tax rate | −0.0% | −3.7% | −0.1% | 0.5% | 0.1% | −0.1% | −0.1% | 0.0% |
| Net profit | -37 | 7 | -51 | -42 | -36 | -36 | -45 | -41 |
| EPS ($ per share) | -2.66 | — | -3.62 | -2.95 | -1.87 | — | -1.82 | -1.23 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -1,424 | -1,865 | -2,309 | -2,833 | -3,201 | -3,477 | -3,596 | -3,760 |
| Total liabilities | 433 | 572 | 461 | 438 | 344 | 267 | 243 | 191 |
| Fixed assets | 49 | 66 | 60 | 61 | 32 | 19 | 3 | 2 |
| Total assets | 2,150 | 1,977 | 1,539 | 1,117 | 711 | 398 | 304 | 280 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 718 | -329 | -313 | -413 | -304 | -193 | -176 | -209 |
| Cash from investing | -1,380 | 207 | 496 | 203 | 366 | 140 | 143 | -1 |
| Cash from financing | 852 | 23 | -80 | 36 | 2 | 0 | 42 | 181 |
| Net cash flow | 190 | -99 | 103 | -174 | 63 | -53 | 9 | -29 |
| Capital expenditure | -14 | -26 | -7 | -15 | -6 | -1 | -1 | -0 |
| Free cash flow | 704 | -355 | -321 | -428 | -310 | -193 | -177 | -209 |
Insider filings
26 filings between Nov 21, 2025 and Sep 23, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$2.43M
16 sales by 3 insiders
44% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 10
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| ROBIN HOWARD W | — | $1.42M | Aug 18, 2026 |
| Zalevsky Jonathan | — | $974.2K | Aug 18, 2026 |
| Wilson Mark Andrew | — | $34.2K | Nov 25, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 23, 2026 | CHESS ROBERT Director | Award | 2,000 | $0 |
| Sep 23, 2026 | GREER R SCOTT Director | Award | 2,000 | $0 |
| Sep 23, 2026 | Ajer Jeffrey Robert Director | Award | 2,000 | $0 |
| Sep 23, 2026 | WHITFIELD ROY A Director | Award | 2,000 | $0 |
| Sep 23, 2026 | Brainard Diana Director | Award | 2,000 | $0 |
| Aug 18, 2026 | Zalevsky Jonathan Chief R&D Officer | Sale | 186 | $13.4K |
| Aug 18, 2026 | ROBIN HOWARD W President & CEO | Sale | 418 | $30.1K |
| Jun 30, 2026 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 plan | 5,681 | $397.7K |
| Jun 17, 2026 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 4,500 | $277.4K |
| Jun 17, 2026 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 5,500 | $334.5K |
| Jun 16, 2026 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 5,303 | $318.0K |
| Jun 16, 2026 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 4,697 | $285.2K |
| Jun 15, 2026 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 plan | 5,538 | $336.2K |
| May 19, 2026 | ROBIN HOWARD W President & CEO | Sale | 444 | $29.1K |
| May 19, 2026 | Zalevsky Jonathan Chief R&D Officer | Sale | 199 | $13.0K |
| Feb 18, 2026 | ROBIN HOWARD W President & CEO | Sale | 423 | $30.9K |
| Feb 18, 2026 | Zalevsky Jonathan Chief R&D Officer | Sale | 180 | $13.1K |
| Jan 20, 2026 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 plan | 3,867 | $137.9K |
| Dec 22, 2025 | Zalevsky Jonathan Chief R&D Officer | Award | 6,250 | $0 |
| Dec 22, 2025 | ROBIN HOWARD W President & CEO | Award | 21,667 | $0 |
| Nov 25, 2025 | Wilson Mark Andrew Chief Legal Officer | Sale | 630 | $34.2K |
| Nov 25, 2025 | ROBIN HOWARD W President & CEO | Sale | 2,207 | $119.8K |
| Nov 25, 2025 | Zalevsky Jonathan Chief R&D Officer | Sale | 1,157 | $62.8K |
| Nov 21, 2025 | ROBIN HOWARD W President & CEO | Award | 7,110 | $0 |
| Nov 21, 2025 | Wilson Mark Andrew Chief Legal Officer | Award | 1,903 | $0 |
| Nov 21, 2025 | Zalevsky Jonathan Chief R&D Officer | Award | 2,666 | $0 |
| Sep 9, 2025 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 1,210 | $58.3K |
| Sep 9, 2025 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 2,156 | $102.4K |
| Sep 9, 2025 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 1,200 | $55.7K |
| Sep 9, 2025 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 2,100 | $94.8K |
| Sep 5, 2025 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 1,136 | $45.3K |
| Sep 5, 2025 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 3,304 | $125.1K |
| Sep 5, 2025 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 2,226 | $86.4K |
| Sep 4, 2025 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 plan | 432 | $14.5K |
| Sep 4, 2025 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 plan | 189 | $6.5K |
| Sep 4, 2025 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 plan | 307 | $11.0K |
| Sep 4, 2025 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 plan | 793 | $25.7K |
| Sep 4, 2025 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 1,134 | $40.6K |
| Sep 4, 2025 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 613 | $21.1K |
| Sep 4, 2025 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 1,496 | $50.2K |
| Sep 4, 2025 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 1,923 | $62.2K |
| Sep 2, 2025 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 plan | 485 | $14.6K |
| Sep 2, 2025 | ROBIN HOWARD W President & CEO | Sale 10b5-1 plan | 1,500 | $45.2K |
| Aug 19, 2025 | ROBIN HOWARD W President & CEO | Sale | 1,573 | $41.8K |
| Aug 19, 2025 | Zalevsky Jonathan Chief R&D Officer | Sale | 725 | $19.3K |
| Aug 19, 2025 | Wilson Mark Andrew Chief Legal Officer | Sale | 676 | $18.0K |
| May 19, 2025 | ROBIN HOWARD W President & CEO | Sale | 23,208 | $15.5K |
| May 19, 2025 | Wilson Mark Andrew Chief Legal Officer | Sale | 9,996 | $6.7K |
| May 19, 2025 | Zalevsky Jonathan Chief R&D Officer | Sale | 10,712 | $7.2K |
| Feb 19, 2025 | ROBIN HOWARD W President & CEO | Sale | 23,774 | $24.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for NEKTAR THERAPEUTICS
Free account. Everything above stays public.
Write why you follow NEKTAR THERAPEUTICS and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading